Ob/Gyn Medical News about Breast Cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pegfilgrastim Administered on the Same Day with Dose-Dense Adjuvant Chemotherapy for Breast Cancer Is Associated with a Higher Incidence of Febrile Neutropenia as Compared to Conventional Growth Factor Support: Matched Case-Control Study of the Hellenic Cooperative Oncology Group
Oncology (Karger), 07/21/09

Skarlos DV et al. – The results demonstrate that pegfilgrastim administered as primary prophylaxis on the same day as dose–dense chemotherapy is less efficacious than filgrastim administered on days 2–10 of each chemotherapy cycle. For the particular regimens given in this retrospective matched case–control study, the current recommendation for administering pegfilgrastim at least 24 h after chemotherapy completion seems justified.

<< Previous
Effects of estrogen replacement therapy on estrogen receptor...

Next >>
Automated Segmentation of Ultrasonic Breast Lesions Using...